Cost-Utility Of Afatinib And Gefitinib As First-Line Treatment For <i>EGFR</i> -Mutated Advanced Non-Small-Cell Lung Cancer

Abstract

First-line afatinib was more cost-effective than gefitinib for EFGR-mutated advanced non-small-cell lung cancer in China.